Annovis Bio Stock Today
| ANVS Stock | USD 2.68 0.17 6.77% |
PerformanceGood
| Odds Of DistressHigh
|
Annovis Bio is selling for under 2.68 as of the 5th of August 2025; that is 6.77 percent increase since the beginning of the trading day. The stock's lowest day price was 2.5. Annovis Bio has more than 67 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 7th of May 2025 and ending today, the 5th of August 2025. Click here to learn more.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. The company has 19.49 M outstanding shares of which 2.46 M shares are presently shorted by private and institutional investors with about 5.65 trading days to cover. More on Annovis Bio
Moving against Annovis Stock
Annovis Stock Highlights
| CEO | Maria Maccecchini |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, NYSE Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Annovis Bio (ANVS) is traded on New York Stock Exchange in USA. It is located in 101 Lindenwood Drive, Malvern, PA, United States, 19355 and employs 8 people. Annovis Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.22 M. Annovis Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 19.49 M outstanding shares of which 2.46 M shares are presently shorted by private and institutional investors with about 5.65 trading days to cover.
Annovis Bio currently holds about 35.97 M in cash with (21.89 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Annovis Bio Probability Of Bankruptcy
Ownership AllocationAnnovis Bio holds a total of 19.49 Million outstanding shares. Annovis Bio shows 14.68 percent of its outstanding shares held by insiders and 16.03 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Annovis Ownership Details
Annovis Bio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Annovis Bio market risk premium is the additional return an investor will receive from holding Annovis Bio long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1297 | |||
| Jensen Alpha | 0.8822 | |||
| Total Risk Alpha | 0.0606 | |||
| Sortino Ratio | 0.1381 |
Annovis Stock Against Markets
Annovis Bio Corporate Management
| Blake Jensen | Head Quality | Profile | |
| Reid McCarthy | Independent Director | Profile | |
| Blake MBA | Head Quality | Profile | |
| Cheng Fang | Senior Development | Profile | |
| Melissa Gaines | Senior Operations | Profile | |
| Mark White | Independent Director | Profile | |
| William CPA | Chief Officer | Profile |
Already Invested in Annovis Bio?
The danger of trading Annovis Bio is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Annovis Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Annovis Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Annovis Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.